SG Americas Securities LLC Lowers Holdings in Kenvue Inc. $KVUE

SG Americas Securities LLC lowered its position in Kenvue Inc. (NYSE:KVUE) by 20.0% during the 1st quarter, Holdings Channel reports. The firm owned 2,461,986 shares of the company’s stock after selling 613,737 shares during the quarter. SG Americas Securities LLC’s holdings in Kenvue were worth $42,445,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of KVUE. Elyxium Wealth LLC bought a new position in shares of Kenvue during the 4th quarter worth $26,000. Physician Wealth Advisors Inc. raised its holdings in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares in the last quarter. MV Capital Management Inc. purchased a new stake in Kenvue in the fourth quarter worth about $28,000. Reflection Asset Management purchased a new stake in Kenvue in the fourth quarter worth about $32,000. Finally, SBI Securities Co. Ltd. lifted its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after acquiring an additional 1,027 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Up 3.1%

Kenvue stock opened at $18.41 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The stock has a market capitalization of $35.35 billion, a price-to-earnings ratio of 21.66, a PEG ratio of 1.36 and a beta of 0.54. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $22.87. The business has a fifty day moving average price of $17.56 and a 200-day moving average price of $17.59.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same period in the prior year, the company posted $0.24 EPS. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. Equities research analysts forecast that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.5%. Kenvue’s dividend payout ratio is 97.65%.

Insider Activity at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.59% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Barclays lowered their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. UBS Group dropped their price objective on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Citigroup cut their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Finally, Argus upgraded Kenvue to a “hold” rating in a report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.